Paris: Sanofi has successfully priced its offering of euro 1.5 billion of notes across 2 tranches:€750 million fixed-rate ...

An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of ...

Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic ...

Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

With skin cancer on the rise across the UK, Boots is expanding dermatology training for its in-store pharmacists. Matt Nixson tried out its mole-scanning service ...